Skip to main content
. 2017 Nov 30;9(6):2018–2033. doi: 10.1016/j.stemcr.2017.10.027

Figure 4.

Figure 4

APLN, OSM, and POSTN Gain-of-Function Experiments

(A–C) Human MPCs were treated with various concentrations of APLN (A1, B1, and C1), OSM (A2, B2, and C2), and POSTN (A3, B3, C3) (1–1,000 nM, 5–100 mg/mL, and 0.1–10 μg/mL, respectively). (A1–A3) MPC proliferation was evaluated using EdU labeling (red). (B1–B3) MPC differentiation was evaluated using labeling for desmin (red) and myogenin (green, arrowheads). (C1–C3) Fusion of differentiated myocytes was evaluated after immunolabeling for desmin (red). Arrowheads show myotubes.

(D) Matrigel plug assay was performed using MPCs with or without recombinant APLN (10 nM), OSM (50 ng/mL), or POSTN (5 μg/mL). Vessel structures were quantified after CD31 (red) labeling.

Blue, Hoechst. Mann-Whitney test was performed versus none: ∗p < 0.05; ∗∗p < 0.01. Results are means ± SEM of six and seven independent in vitro and in vivo experiments, respectively. Bars, 50 μm. See also Figures S1 and S2.